Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Maastricht University Medical Center
Eli Lilly and Company
OHSU Knight Cancer Institute
Bristol-Myers Squibb